Atomoxetine Treatment of Attention Deficit/Hyperactivity Disorder Symptoms in 3–6-Year-Old Children with Autism Spectrum Disorder
A Retrospective Cohort Study
Bibliographic Data
| ID | 15718769 |
|---|---|
| Authors | Hamza A Alsayouf (0000-0002-3646-7599, Jordan Hospital, corresponding author), Osama Alsarhan (Jordan Hospital), Wael Khreisat (0000-0002-0422-6467, King Hussein Medical Center), Azhar S Daoud (Specialty Hospital, Jordan), Azhar Daoud (The Specialty Hospital, Amman 11942, Jordan) |
| Year | 2024 |
| Volume | 11 |
| Issue | 2 |
| Pages | 163-163 |
| Publication date | 2024-01-26 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Children (JOURNAL) |
| Journal identifiers | ISSN: 2227-9067 • E-ISSN: 2227-9067 |
| Publisher | Multidisciplinary Digital Publishing Institute (PUBLISHER • CH) |
| DOI | 10.3390/children11020163 |
| PMID | 38397275 |
| OpenAlex | W4391252812 |
| Language | EN |
| Citations received | 2 |
| References cited | 33 |
Atomoxetine is indicated for the management of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 18 years. Few studies have assessed the safety and tolerability of atomoxetine in younger patients. This retrospective cohort study included 133 children aged 3-6 years who were diagnosed with ADHD comorbid with autism spectrum disorder (ASD). The primary endpoint was the evaluation of the safety profile of atomoxetine. In total, 50 patients (37.6%) experienced adverse events (AEs), which led to treatment discontinuation in 23 patients (17.3%). The most common AEs were gastrointestinal (24.1%), aggression or hostility (12.8%), and increased hyperactivity (9.0%). In the 23 patients who discontinued treatment, all the AEs resolved after treatment ceased. Among the 110 patients who completed at least 6 months' treatment, atomoxetine titrated to a dose of 1.2-1.8 mg/kg/day appeared to be well tolerated and effective. The Clinical Global Impression-Improvement score improved to 1 ("very much improved") and 2 ("much improved") in 62.4% and 20.3% of children, respectively, at their last visit. Overall, atomoxetine appeared to be well tolerated in younger children with comorbid ADHD and ASD. Nevertheless, close patient monitoring remains essential, and the study limitations necessitate caution in generalizing these findings to broader populations. Long-term prospective studies are required
Adverse effect · Atomoxetine · Autism · Autism spectrum disorder · Cohort · Comorbidity · Discontinuation · Methylphenidate · Psychiatry · Retrospective cohort study · Tolerability · Attention Deficit Hyperactivity Disorder · Autism Spectrum Disorder Research · Child and Adolescent Psychosocial and Emotional Development · Medicine · Internal Medicine · Pediatrics
Misuse of the Term Retrospective Cohort. Comment on Alsayouf et al. Atomoxetine Treatment of Attention Deficit/Hyperactivity Disorder Symptoms in 3–6-Year-Old Children with Autism Spectrum Disorder
Growing evidence of pharmacotherapy effectiveness in managing attention-deficit/hyperactivity disorder in young children with or without autism spectrum disorder
Diagnostic and Statistical Manual of Mental Disorders
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Common emotional and behavioral disorders in preschool children
Schooling and Occupational Outcomes in Adults with ADHD
| Citations per year | 1 |
|---|---|
| Citation span | 2024 - 2024 (1) |
| Highly cited | No |